Related Experiment Video
Updated: Aug 22, 2025
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Novel Therapeutic Approaches Enhance PGC1-alpha to Reduce Oxidant Stress-Inflammatory Signaling and Improve
Rishav Aggarwal1, Koray N Potel2, Edward O McFalls3
1Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Insights
Ischemic heart disease impacts millions globally. Enhancing PGC1-alpha signaling via mesenchymal stem cells may improve recovery after bypass surgery for hibernating myocardium.
Area of Science:
- Cardiovascular Biology
- Mitochondrial Metabolism
- Cellular Stress Response
Background:
- Ischemic heart disease (IHD) affects millions, with current treatments like coronary artery bypass grafting (CABG) offering incomplete functional recovery.
- Myocardial hibernation, a response to prolonged ischemia, involves metabolic adaptations but can lead to persistent pro-oxidant and inflammatory signaling, hindering recovery.
- PGC1-alpha, a regulator of mitochondrial function and inflammation, is downregulated in hibernating myocardium, contributing to impaired recovery.
Purpose of the Study:
- To explore the role of PGC1-alpha signaling in myocardial hibernation and its potential as a therapeutic target.
- To investigate the efficacy of adjunctive mesenchymal stem cell (MSC) therapy in enhancing PGC1-alpha signaling in hibernating myocardium.
- To assess the potential of this approach to improve functional recovery in patients with IHD undergoing revascularization.
Main Methods:
- Review of literature on myocardial hibernation, PGC1-alpha regulation, and stem cell therapy in ischemic heart disease.
- Analysis of the molecular mechanisms linking PGC1-alpha, mitochondrial metabolism, and inflammatory signaling in the ischemic heart.
- Evaluation of preclinical and clinical evidence supporting MSC therapy for inducing PGC1-alpha signaling.
Main Results:
- PGC1-alpha is a critical mediator of cellular adaptation to ischemia, balancing metabolic demands and inflammatory responses.
- Downregulation of PGC1-alpha in chronic hibernation contributes to persistent metabolic dysfunction and tissue injury.
- Mesenchymal stem cell therapy has demonstrated the ability to upregulate PGC1-alpha signaling in hibernating myocardium.
Conclusions:
- Enhancing PGC1-alpha signaling represents a promising strategy to improve functional recovery in ischemic heart disease.
- Adjunctive mesenchymal stem cell therapy may serve as an effective means to boost PGC1-alpha activity in hibernating myocardium.
- This approach holds potential for improving clinical outcomes in patients with ischemic heart disease undergoing bypass surgery.
Abstract:
Ischemic heart disease affects millions of people around the world. Current treatment options, including coronary artery bypass grafting, do not result in full functional recovery, highlighting the need for novel adjunctive therapeutic approaches. Hibernation describes the myocardial response to prolonged ischemia and involves a set of complex cytoprotective metabolic and functional adaptations. PGC1-alpha, a key regulator of mitochondrial energy metabolism and inhibitor of oxidant-stress-inflammatory signaling, is known to be downregulated in hibernating myocardium. PGC1-alpha is a critical component of cellular stress responses and links cellular metabolism with inflammation in the ischemic heart. While beneficial in the acute setting, a chronic state of hibernation can be associated with self-perpetuating oxidant stress-inflammatory signaling which leads to tissue injury. It is likely that incomplete functional recovery following revascularization of chronically ischemic myocardium is due to persistence of metabolic changes as well as prooxidant and proinflammatory signaling. Enhancement of PGC1-alpha signaling has been proposed as a possible way to improve functional recovery in patients with ischemic heart disease. Adjunctive mesenchymal stem cell therapy has been shown to induce PGC1-alpha signaling in hibernating myocardium and could help improve clinical outcomes for patients undergoing bypass surgery.
